/NAMS
NAMS Stock - NewAmsterdam Pharma Company N.V.
Healthcare|BiotechnologyNASDAQ
$35.11+3.57%
+$1.21 (+3.57%) • Dec 19
82
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.69
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+26.7%upside
Target: $44.48
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NAMS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$34.76 – $35.46
TARGET (TP)$44.50
STOP LOSS$32.30
RISK/REWARD1:3.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.05
52W High$42.00
52W Low$14.06
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $45.56M | $14.09M | $102.69M | N/A | N/A |
| Gross Profit | $45.56M | $14.09M | $102.69M | N/A | N/A |
| Gross Margin | 100.0% | 100.0% | 100.0% | N/A | N/A |
| Operating Income | $-176,289,000 | $-182,967,000 | $-3,557,000 | $-34,977,000 | $-6,632,054 |
| Net Income | $-241,598,000 | $-176,937,000 | $-22,634,000 | $-41,785,000 | $-7,022,966 |
| Net Margin | -530.3% | -1255.8% | -22.0% | N/A | N/A |
| EPS | $-2.56 | $-2.15 | $-1.11 | $-3.34 | $-1.15 |
Company Overview
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
12
92%
Hold / Neutral
1
8%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
12 Bullish1 Neutral/Bearish
Price Targets
$35
Average Target
↓ 0.1% Downside
Now
$19
Low
$35
Average
$52
High
Based on 14 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 20th 2025 | H.C. Wainwright | Resumed | Buy | $52 |
| August 25th 2025 | Wells Fargo | Initiation | Overweight | $45 |
| July 17th 2025 | Goldman | Initiation | Neutral | $27 |
| June 17th 2025 | Citigroup | Initiation | Buy | $42 |
| June 10th 2025 | Stifel | Initiation | Buy | $44 |
| June 4th 2025 | Cantor Fitzgerald | Initiation | Overweight | $42 |
| December 30th 2024 | H.C. Wainwright | Initiation | Buy | $48 |
| May 15th 2024 | TD Cowen | Initiation | Buy | - |
| March 14th 2024 | Scotiabank | Initiation | Sector Outperform | $35 |
| January 18th 2024 | Guggenheim | Initiation | Buy | $30 |
| January 16th 2024 | Piper Sandler | Initiation | Overweight | $37 |
| October 30th 2023 | RBC Capital Mkts | Initiation | Outperform | $25 |
| January 6th 2023 | Credit Suisse | Initiation | Outperform | $21 |
| December 20th 2022 | SVB Leerink | Initiation | Outperform | $19 |
| December 19th 2022 | William Blair | Initiation | Outperform | - |
Earnings History & Surprises
NAMSBeat Rate
42%
Last 12 quarters
Avg Surprise
-25.1%
EPS vs Estimate
Beats / Misses
5/7
Last 12 quarters
Latest EPS
$-0.41
Q4 2025
EPS Surprise History
Q1 24
+5.5%
$-0.57vs$-0.60
Q2 24
-14.8%
$-0.62vs$-0.54
Q3 24
+13.6%
$-0.51vs$-0.59
Q4 24
+62.5%
$-0.18vs$-0.48
Q1 25
-97.9%
$-0.95vs$-0.48
Q2 25
-8.9%
$-0.49vs$-0.45
Q3 25
+71.2%
$-0.15vs$-0.52
Q4 25
-7.9%
$-0.41vs$-0.38
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.40 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.38 | $-0.41 | -7.9% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-0.52 | $-0.15 | +71.2% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.45 | $-0.49 | -8.9% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $-0.48 | $-0.95 | -97.9% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.48 | $-0.18 | +62.5% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-0.59 | $-0.51 | +13.6% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.54 | $-0.62 | -14.8% | ✗ MISS |
Q1 2024 | Mar 29, 2024 | $-0.60 | $-0.57 | +5.5% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.55 | $-0.54 | +1.8% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.39 | $-0.47 | -19.9% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $-0.44 | $-0.52 | -17.2% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $-0.61 | $-2.37 | -289.0% | ✗ MISS |
Q4 2022 | Oct 18, 2022 | — | $-2.14 | — | — |
Q2 2022 | Jun 30, 2022 | — | $1.61 | — | — |
Q1 2022 | Mar 30, 2022 | — | $1.70 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-1.13 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.63 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.32 | — | — |
Latest News
Stifel Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $50
📈 PositiveBenzinga•Dec 16, 2025, 05:28 PM•Also:
Goldman Sachs Maintains Neutral on NewAmsterdam Pharma Co, Raises Price Target to $37
➖ NeutralBenzinga•Dec 2, 2025, 06:14 PM
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $44
📈 PositiveBenzinga•Nov 6, 2025, 04:22 PM
Needham Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $46
📈 PositiveBenzinga•Nov 5, 2025, 06:11 PM
NewAmsterdam Pharma Q3 EPS $(0.61) Misses $(0.41) Estimate, Sales $348.000K Miss $5.287M Estimate
📉 NegativeBenzinga•Nov 5, 2025, 01:07 PM
HC Wainwright & Co. Assumes NewAmsterdam Pharma Co at Buy, Announces Price Target of $52
📈 PositiveBenzinga•Oct 20, 2025, 10:46 AM
Citigroup Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $50
📈 PositiveBenzinga•Oct 17, 2025, 03:27 PM•Also:
Wells Fargo Initiates Coverage On NewAmsterdam Pharma Co with Overweight Rating, Announces Price Target of $45
📈 PositiveBenzinga•Aug 25, 2025, 11:27 AM
NewAmsterdam Pharma And Piramal Pharma Solutions Invest Multi-Million Dollars In Dedicated Oral Solid Dosage Suite At Sellersville Pennsylvania Facility
📈 PositiveBenzinga•Aug 21, 2025, 07:24 AM
Frequently Asked Questions about NAMS
What is NAMS's current stock price?
NewAmsterdam Pharma Company N.V. (NAMS) is currently trading at $35.11 per share. The stock has moved +3.57% today.
What is the analyst price target for NAMS?
The average analyst price target for NAMS is $44.50, based on 1 analyst.
What sector is NewAmsterdam Pharma Company N.V. in?
NewAmsterdam Pharma Company N.V. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NAMS's market cap?
NewAmsterdam Pharma Company N.V. has a market capitalization of $3.98 billion, making it a mid-cap company.
Does NAMS pay dividends?
No, NewAmsterdam Pharma Company N.V. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACLX
Arcellx, Inc.
$63.96
Mkt Cap: $3.5B
AKRO
Akero Therapeutics, Inc.
$54.65
Mkt Cap: $4.5B
CGON
CG Oncology, Inc. Common stock
$39.03
Mkt Cap: $2.9B
CRNX
Crinetics Pharmaceuticals, Inc.
$48.01
Mkt Cap: $4.6B
IMVT
Immunovant, Inc.
$26.68
Mkt Cap: $4.7B
KYMR
Kymera Therapeutics, Inc.
$83.99
Mkt Cap: $6.0B
LGND
Ligand Pharmaceuticals Incorporated
$200.33
Mkt Cap: $3.9B
PRAX
Praxis Precision Medicines, Inc.
$272.92
Mkt Cap: $5.8B
SLNO
Soleno Therapeutics, Inc.
$47.85
Mkt Cap: $2.6B
VKTX
Viking Therapeutics, Inc.
$35.19
Mkt Cap: $4.0B
Explore stocks similar to NAMS for comparison